AMLER, LUKAS C.,BIRKNER, MERRILL,LIN, CHIN-YU,MOECKS, JOACHIM,STRAUSS, ANDREAS
申请号：
PL08731126
公开号：
PL2132573T3
申请日:
2008.02.29
申请国别(地区):
PL
年份:
2014
代理人:
摘要：
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
